O besity is well recognized as a determinant of cardiovascular and other chronic diseases (1-4). More recently, obesity and the metabolic syndrome have been recognized as risk factors for the development and progression of chronic kidney disease (CKD). In this issue of JASN, Ejerblad et al. (5) present results from a population-based casecontrol study conducted in Sweden from 1996 to 1998, examining the association of lifestyle factors with CKD. In this report, the authors compared the likelihood of prevalent CKD, defined as a serum creatinine concentration consistently Ͼ3.4 mg/dl in men and Ͼ2.8 mg/dl in women, by body size determined using the Quetèlet (body mass) index, with separate analyses conducted for current values, highest-ever values, and Quetèlet index at age 20 yr. Participation rates were relatively high (78% in cases, 75% in controls). Analyses were adjusted for age, education or income, and the use of tobacco, alcohol, and analgesic medications; stratified analyses by diabetes status and the presumed cause of CKD were also presented.
O besity is well recognized as a determinant of cardiovascular and other chronic diseases (1) (2) (3) (4) . More recently, obesity and the metabolic syndrome have been recognized as risk factors for the development and progression of chronic kidney disease (CKD). In this issue of JASN, Ejerblad et al. (5) present results from a population-based casecontrol study conducted in Sweden from 1996 to 1998, examining the association of lifestyle factors with CKD. In this report, the authors compared the likelihood of prevalent CKD, defined as a serum creatinine concentration consistently Ͼ3.4 mg/dl in men and Ͼ2.8 mg/dl in women, by body size determined using the Quetèlet (body mass) index, with separate analyses conducted for current values, highest-ever values, and Quetèlet index at age 20 yr. Participation rates were relatively high (78% in cases, 75% in controls). Analyses were adjusted for age, education or income, and the use of tobacco, alcohol, and analgesic medications; stratified analyses by diabetes status and the presumed cause of CKD were also presented.
The current Quetèlet index was not associated with the odds of prevalent CKD. When considering the highest ever Quetèlet index, the odds of prevalent CKD were increased 1. When considering Quetèlet index Ն25 kg/m 2 at age 20 yr, the odds of prevalent CKD were increased three-fold in men and women. The association between highest-ever Quetèlet index and prevalent CKD was strongest among persons with diabetes; Quetèlet index Ն25 kg/m 2 at age 20 yr was associated with prevalent CKD among all primary disease subgroups.
The results presented by Ejerblad et al. are consistent with several recent reports on the link between obesity (rather, proxies of obesity) and kidney disease. Data from both the Framingham Offspring cohort (7) and the Hypertension Detection and Follow-Up Program (8) showed that higher Quetèlet index was associated with an increased risk of new onset CKD (defined in the first study as an estimated GFR [eGFR] Ͻ59 ml/min per 1.73 m 2 in women and Ͻ64 ml/min per 1.73 m 2 in men, and in the second study as eGFR Ͻ60 ml/min per 1.73 m 2 or 1ϩ proteinuria).
Considering the broader criteria for the metabolic syndrome, Chen et al. (9) showed there was a cross-sectional association between prevalent CKD (defined as eGFR Ͻ60 ml/min per 1.73 m 2 ) with the metabolic syndrome in the Third National Health (13) . Other findings are noteworthy. The absence of an association between current Quetèlet index and CKD might be explained by weight loss as a consequence of advanced CKD, as the authors suggest. However, it may also be a result of competing mortality risks for older persons with longer standing obesity. While the authors did not identify a statistically significant Quetèlet index by sex interaction, the association between Quetèlet index and CKD appeared to be stronger in men than in women, as suggested in other studies. Whether this reflects a difference in competing mortality risks, misclassification of adiposity (14) , or a true biologic difference is unknown. Finally, while commonly used, the Quetèlet index may not be the ideal proxy for adiposity, particularly among persons with CKD. The Quetèlet index does not reliably reflect differences in body composition, where higher body weight associated with muscle and fat (or edema) cannot be distinguished. Indeed, studies in the general population have demonstrated higher risks of death and cardiovascular disease associated with larger waist circumference, even after adjusting for Quetèlet index (15, 16) . Studies in ESRD have shown that other proxies of body composition (e.g., phase angle and vector length by bioelectrical impedance analysis) also have prognostic significance (17, 18) .
In summary, over the past several years, several cross-sectional and longitudinal studies from diverse populations have secured the importance of higher body weight for height as a risk factor for the prevalence and progression of CKD. The nephrology community has been perplexed and somewhat paralyzed by the paradoxical association between higher body weight for height and survival among hemodialysis patients (19 -21) , a finding almost certainly explained by residual confounding by malnutrition and competing mortality risks in the years preceding ESRD. The Ejerblad et al. study augments the ever-fattening evidence base that obesity is linked to kidney disease. National and international educational efforts on weight control, diabetes, metabolic syndrome, and related conditions should include discussion of the risks of CKD and ESRD. Moreover, long-term cohort studies and clinical trials examining body weight and composition should consider progressive CKD among the many preventable consequences of obesity.
